1. Home
  2. SHLS vs NTLA Comparison

SHLS vs NTLA Comparison

Compare SHLS & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shoals Technologies Group Inc.

SHLS

Shoals Technologies Group Inc.

HOLD

Current Price

$6.20

Market Cap

1.4B

Sector

Technology

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$13.41

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHLS
NTLA
Founded
1996
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
SHLS
NTLA
Price
$6.20
$13.41
Analyst Decision
Buy
Buy
Analyst Count
14
20
Target Price
$9.21
$20.45
AVG Volume (30 Days)
5.8M
3.6M
Earning Date
05-27-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
42.86
27.43
EPS
0.20
N/A
Revenue
$475,331,000.00
$67,671,000.00
Revenue This Year
$25.90
N/A
Revenue Next Year
$11.21
$73.07
P/E Ratio
$30.65
N/A
Revenue Growth
19.07
16.92
52 Week Low
$2.92
$5.90
52 Week High
$11.36
$28.24

Technical Indicators

Market Signals
Indicator
SHLS
NTLA
Relative Strength Index (RSI) 35.77 52.33
Support Level $5.49 $10.44
Resistance Level $6.26 $15.06
Average True Range (ATR) 0.43 0.96
MACD 0.01 -0.12
Stochastic Oscillator 35.11 29.56

Price Performance

Historical Comparison
SHLS
NTLA

About SHLS Shoals Technologies Group Inc.

Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: